2.4400 0.00 (0.00%)
After hours: 5:55PM EDT
|Bid||2.3700 x 1400|
|Ask||5.7500 x 800|
|Day's Range||2.2900 - 2.5100|
|52 Week Range||2.2900 - 17.6600|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.50|
Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced new additions to its leadership team. Matthew Osborne will be joining as Chief Financial Officer, effective June 24, 2019. Jessica Sachs, M.D., will become Chief Medical Officer, effective July 15, 2019, replacing Michael Vasconcelles, M.D., who is transitioning to a clinical advisory role and departing the company.
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -2.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing.
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., May 06, 2019 -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to.
Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.
A look at the shareholders of Unum Therapeutics Inc. (NASDAQ:UMRX) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies...
CAMBRIDGE, Mass., April 02, 2019 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to.
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in.
CAMBRIDGE, Mass., March 21, 2019 -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to.
In a release issued yesterday under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed.
- Multiple Data Readouts from ATTCK-20-03 and ATTCK-17-01 Expected in 2019 - - Initial Data on ATTCK-34-01, Unum’s First Program in Solid Tumors, Expected in Second Half of.
Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that Christiana Stamoulis, President and Chief Financial Officer, will be stepping down from the Company, effective January 31, 2019, to pursue another opportunity. Ms. Stamoulis will work closely with management to ensure a smooth transition to her successor. “I am fortunate to have worked at such a remarkable organization and to have been a part of Unum’s transformation from a very early-stage startup into a fast-growing public company in the high-potential field of cancer cell therapy,” said Ms. Stamoulis.
CAMBRIDGE, Mass., Dec. 20, 2018 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular.
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
US Patent and Trademark Office Issues US Patent 10,144,770 Covering Antibody-Coupled T-cell Receptors (ACTR)Broad Claims Provide Composition of Matter Protection for Cell.
- Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose Level 2 - - No SAEs of Cytokine Release Syndrome or Neurological Events.
CAMBRIDGE, Mass., Dec. 01, 2018 -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in.
Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that the Company will host an investor event to discuss its efforts in solid tumors on Monday November 12, 2018, from 8:30 a.m. to 10:00 a.m. ET in New York City. In addition, the Company will discuss the unmet need, clinical validation of ACTR707 and design of the ATTCK-34-01 Phase I trial using ACTR707 in combination with trastuzumab to target HER2-positive advanced cancers. The Company also will provide more details on the new BOXR platform to support its growing efforts in solid tumors.
- ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL – - New Solid Tumors Technology Platform Revealed at SITC –.